Journal Articles
2020

The Role of Chest Imaging in Patient Management during the
COVID-19 Pandemic: A Multinational Consensus Statement from
the Fleischner Society.
G. D. Rubin
C. J. Ryerson
L. B. Haramati
N. Sverzellati
J. P. Kanne

See next page for additional authors

Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Critical Care Commons

Recommended Citation
Rubin GD, Ryerson CJ, Haramati LB, Sverzellati N, Kanne JP, Raoof S, Schluger NW, Volpi A, Yim J, Leung
AN, . The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational
Consensus Statement from the Fleischner Society.. . 2020 Jan 01; 296(1):Article 6209 [ p.]. Available
from: https://academicworks.medicine.hofstra.edu/articles/6209. Free full text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic
Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara
Zucker School of Medicine Academic Works. For more information, please contact academicworks@hofstra.edu.

Authors
G. D. Rubin, C. J. Ryerson, L. B. Haramati, N. Sverzellati, J. P. Kanne, S. Raoof, N. W. Schluger, A. Volpi, J.
Yim, A. N. Leung, and +10 additional authors

This article is available at Donald and Barbara Zucker School of Medicine Academic Works:
https://academicworks.medicine.hofstra.edu/articles/6209

The Role of Chest Imaging in Patient Management
during the COVID-19 Pandemic:
A Multinational Consensus Statement from the
Fleischner Society
Geoffrey D. Rubin, Department of Radiology, Duke
University School of Medicine, Durham North Carolina
Linda B. Haramati, Department of Radiology,
Montefiore Medical Center, Albert Einstein College of
Medicine, Bronx, NY
Jeffrey P. Kanne, Department of Radiology, University
of Wisconsin School of Medicine and Public Health,
Madison, Wisconsin
Neil W. Schluger, Division of Pulmonary, Allergy and
Critical Care Medicine, Columbia University Irving
Medical Center, New York
Jae-Joon Yim, Division of Pulmonary and Critical
Medicine, Seoul National University College of
Medicine, Seoul, South Korea
Deverick J. Anderson, Director, Duke Center for
Antimicrobial Stewardship and Infection Prevention,
Duke University Medical Center, Durham, NC
Talissa Altes, Department of Radiology, University of
Missouri, Columbia, Missouri

Christopher J. Ryerson, Department of Medicine,
University of British Columbia, Vancouver, Canada
Nicola Sverzellati, Scienze Radiologiche, Department
of Medicine and Surgery, University of Parma, Parma
Italy
Suhail Raoof, Division of Pulmonary, Critical Care &
Sleep Medicine, Lenox Hill Hospital, New York, New
York
Annalisa Volpi, 1st Anestethesia and Intensive Care
Unit, University Hospital of Parma, Parma, Italy
Ian B. K. Martin, Department of Emergency Medicine
The Medical College of Wisconsin School of Medicine,
Milwaukee, WI
Christina Kong, Medical Director of Pathology and
Clinical Laboratory Medicine,Stanford University
Medical Center, Stanford, California
Andrew Bush, Department of Paediatrics and
Paediatric Respirology, Royal Brompton Hospital,
London, United Kingdom
Jonathan Goldin, Department of Radiology, David
Geffen School of Medline at University of California
Los Angeles

Sujal R. Desai, Department of Radiology, Royal
Brompton & Harefield NHS Foundation Trust, London
AND National Heart and Lung Institute, Imperial
College, London, United Kingdom
Jin Mo Goo, Department of Radiology, Seoul National
University College of Medicine, Seoul, South Korea

Marc Humbert, Department of Respiratory and
Intensive Care Medicine, Université Paris-Saclay,
Hôpital Bicêtre, Le Kremlin-Bicêtre, France
Hans-Ulrich Kauczor, Diagnostic and Interventional
Radiology, University Hospital Heidelberg, Germany

Yoshikazu Inoue, Department of Pathology, National
Hospital Organization Kinki-Chuo Chest Medical
Center, Osaka, Japan
Fengming Luo, Department of Pulmonary and Critical
Care Medicine, West China Hospital, Sichuan
University, China
Mathias Prokop, Department of Radiology and Nuclear
Medicine, Radboud University Medical Center,
Nijmegen, the Netherlands
Luca Richeldi, Division of Pulmonary Medicine,
Università Cattolica del Sacro Cuore, Rome, Italy

Peter J. Mazzone, Respiratory Institute, Cleveland
Clinic, Cleveland, Ohio
Martine Remy-Jardin, Department of Thoracic Imaging
- Hospital Calmette, University Centre of Lille. Lille,
France
Cornelia M. Schaefer-Prokop, Department of
Radiology and Nuclear Medicine, Meander Medical
Centre, Amersfoort, the Netherlands
Athol U. Wells, Department of Pulmonary Medicine,
Royal Brompton Hospital, London, United Kingdom

Noriyuki Tomiyama, Department of Radiology, Osaka
University Graduate School of Medicine, Osaka, Japan
Ann N. Leung, Department of Radiology, Stanford
University School of Medicine, Stanford, California

1
This copy is for personal use only. To order printed copies, contact reprints@rsna.org

Address correspondence to G.D.R., Department of Radiology, Duke University School of
Medicine, Box 3808 DUMC, Durham, NC 27710 (e-mail: grubin@duke.edu).

Essentials
 Imaging is not indicated in patients with suspected COVID-19 and mild clinical features
unless they are at risk for disease progression.
 Imaging is indicated in a patient with COVID-19 and worsening respiratory status.
 In a resource-constrained environment, imaging is indicated for medical triage of
patients with suspected COVID-19 who present with moderate-severe clinical features
and a high pre-test probability of disease.
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Abstract
With more than 900,000 confirmed cases worldwide and nearly 50,000 deaths during the first
three months of 2020, the COVID-19 pandemic has emerged as an unprecedented healthcare
crisis. The spread of COVID-19 has been heterogeneous, resulting in some regions having
sporadic transmission and relatively few hospitalized patients with COVID-19 and others having
community transmission that has led to overwhelming numbers of severe cases. For these
regions, healthcare delivery has been disrupted and compromised by critical resource
constraints in diagnostic testing, hospital beds, ventilators, and healthcare workers who have
fallen ill to the virus exacerbated by shortages of personal protective equipment. While mild
cases mimic common upper respiratory viral infections, respiratory dysfunction becomes the
principal source of morbidity and mortality as the disease advances. Thoracic imaging with
chest radiography (CXR) and computed tomography (CT) are key tools for pulmonary disease
diagnosis and management, but their role in the management of COVID-19 has not been
considered within the multivariable context of the severity of respiratory disease, pre-test
probability, risk factors for disease progression, and critical resource constraints. To address
this deficit, a multidisciplinary panel comprised principally of radiologists and pulmonologists
from 10 countries with experience managing COVID-19 patients across a spectrum of
healthcare environments evaluated the utility of imaging within three scenarios representing
varying risk factors, community conditions, and resource constraints. Fourteen key questions,
corresponding to 11 decision points within the three scenarios and three additional clinical
situations, were rated by the panel based upon the anticipated value of the information that
thoracic imaging would be expected to provide. The results were aggregated, resulting in five
main and three additional recommendations intended to guide medical practitioners in the use
of CXR and CT in the management of COVID-19.

Editor's note: This article is being simultaneously published in Chest.
© 2020 RSNA; American College of Chest Physicians, published by Elsevier Inc.
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On March 11, 2020 the World Health Organization (WHO) officially characterized the rapid
global spread of coronavirus disease 2019 (COVID-19) as a pandemic and called for urgent
international action in four key areas: to prepare and be ready; detect, protect, and treat;
reduce transmission; and innovate and learn (1). At the time of writing (April 1, 2020), there are
over 900,000 confirmed COVID-19 cases and nearly 50,000 deaths in 205 countries around the
world, with the majority of cases concentrated in 4 countries: United States, Italy, Spain, and
China (2, 3). With sustained community transmission now established in multiple countries on
multiple continents, the WHO public health goal has changed from containment to mitigation
of the pandemic’s impact. Consequently, strategies are now focused on efforts to reduce the
incidence, morbidity, and mortality of COVID-19 by breaking the chain of human transmission
through social distancing and imposed quarantine.
Diagnostic Testing
Early detection and containment of infection caused by the novel coronavirus SARS-CoV2 has
been hindered by the need to develop, mass produce, and widely disseminate the required
molecular diagnostic test, a real-time reverse transcriptase-polymerase chain reaction (RT-PCR)
assay. Early reports of test performance in the Wuhan outbreak showed variable sensitivities
ranging from 37% to 71% (4, 5). While laboratory-based performance evaluations of RT-PCR
test show high analytical sensitivity and near-perfect specificity with no misidentification of
other coronaviruses or common respiratory pathogens, test sensitivity in clinical practice may
be adversely affected by a number of variables including: adequacy of specimen, specimen
type, specimen handling, and stage of infection when the specimen is acquired (CDC guidelines
for in-vitro diagnostics) (6, 7). False negative RT-PCR tests have been reported in patients with
CT findings of COVID-19 who were eventually tested positive with serial sampling (8). Limited
testing capacity due to insufficient specimen collection kits, lab test supplies, and testing
equipment precluded early widespread testing and is believed to have contributed to rapid and
unchecked transmission of infection within communities by undetected individuals with milder,
limited, or no symptoms (9, 10). For example, CT screening of 82 asymptomatic individuals with
confirmed COVID-19 from the cruise ship “Diamond Princess” showed findings of pneumonia in
54% (11).

Imaging Logistics During Pandemic
4

Provision of diagnostic imaging services to large numbers of patients suspected or confirmed to
have COVID-19 during an outbreak can be challenging, as each study is lengthened and
complicated by the need for strict adherence to infection control protocols designed to
minimize risk of transmission and protect healthcare personnel (12). Droplet transmission
followed by contaminated surfaces are believed to be the main modes of spread for SARS-CoV2
in radiology suites; all patients undergoing imaging should be masked and imaged using
dedicated equipment that is cleaned and disinfected after each patient encounter (13).
Although personal protection equipment (PPE) recommendations vary between countries, the
current Centers of Disease Control (CDC) guidelines recommend radiology staff wear a mask,
goggles or face shield, gloves, and an isolation gown. In countries with more stringent PPE
protocols, a surgical cap and shoe covers may be added, while a surgical mask and goggles or
face shield are suggested in some countries with less stringent PPE protocols (14). Additional
precautions are required for specific situations that are more likely to generate aerosols,
including patients receiving non-invasive ventilation, during intubation or extubation,
throughout bronchoscopy, or when receiving nebulized therapies. Portable imaging, including
imaging patients through glass walls, has been used in some hospitals to further reduce the
chance of spreading infection.
Written from multidisciplinary and multinational perspectives, this Fleischner statement is
intended to provide context for the use of imaging to direct patient management during the
COVID-19 pandemic in different practice settings, different phases of epidemic outbreak, and
environments of varying critical resource availability. This document is structured around three
clinical scenarios and three additional situations in which chest imaging is often considered in
the evaluation of patients with potential COVID-19 infection. The committee elected to present
this document as a consensus statement rather than a guideline given the limited evidence
base and the urgent need for direction on this topic for the medical community.
Methods
This Consensus Statement is based upon expert opinion amongst a panel of 15 thoracic
radiologists, 10 pulmonologists/intensivists (including one anesthesiologist), and 1 pathologist,
as well as additional experts in emergency medicine, infection control, and laboratory
5

medicine. The panel included individuals from the United States, Italy, China, Germany, France,
United Kingdom, Netherlands, South Korea, Canada, and Japan, representing 9 of the 15
countries with the highest number of confirmed COVID-19 cases reported worldwide as of April
1, 2020 (2). The panel possessed experience managing patients during periods of local viral
amplification and critical resource constraints in Wuhan China, Northern Italy, and New York
City.
A subcommittee composed of five radiologists, four pulmonologists/intensivists (including one
anesthesiologist), and one emergency medicine physician identified and iteratively developed
three scenarios that illustrate imaging-related dilemmas occurring in common clinical
presentations and across varying risk factors, community conditions, and resource constraints.
These scenarios included 11 distinct nodes where imaging potentially provides clinically
actionable information (Figs 1, 2, 3), with three additional situations identified in which chest
imaging is also often considered (Fig 4). The entire panel was convened during a single session
using a live audio and video interface (Zoom Video Communications, San Jose, CA). The three
scenarios and three additional situations were presented, discussed, and refined. The panel
independently and anonymously rated the appropriateness of imaging with chest radiography
(CXR) or CT at each of these decision points on a five-point scale. At least 70% agreement on
the direction of a recommendation was considered consensus. The scenarios are intended to
support the management of adults only. Children, who are typically spared from severe
infections (15), merit separate consideration, particularly with regard to use of radiationassociated procedures, and are beyond the scope of the current document.
The final document was supported by a comprehensive literature search for relevant articles.
Using the search terms “((coronavirus OR COVID OR SARS-CoV OR *nCoV*) AND (CT OR
Computed Tomography OR Radio* OR Imag*))”, a total of 137 English articles published

between Dec 1, 2019 and March 23, 2020 were identified. Each article was assessed for
relevance to the primary objective and a summary of key findings from relevant articles was
created.
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The Use of Imaging in COVID-19
The value of an imaging test relates to the generation of results that are clinically actionable
either for establishing a diagnosis or for guiding management, triage, or therapy. That value is
diminished by costs that include the risk of radiation exposure to the patient, risk of COVID-19
transmission to uninfected healthcare workers and other patients, consumption of PPE, and
need for cleaning and downtime of radiology rooms in resource-constrained environments. The
appropriate use of imaging in each of the scenarios was considered on this basis.
This statement focuses exclusively on the use of chest radiography (CXR) and computed
tomography of the thorax (CT). While ultrasound has been suggested as a potential triage and
diagnostic tool for COVID-19 given the predilection for the disease in subpleural regions, there
is limited experience at this time (16), as well as infection control issues.
CXR is insensitive in mild or early COVID-19 infection (17). However, with respect to the relative
value of CXR or CT for detecting the presence of viral pneumonia, the experience is vastly
different dependent upon community norms and public health directives. When patients are
encouraged to present early in the course of their disease, as was the case in Wuhan, China,
CXR has little value. The greater sensitivity of CT for early pneumonic changes is more relevant
in the setting of a public health approach that required isolation of all infected patients within
an environment where the reliability of COVID-19 testing was limited and turnaround times
were long (4). Alternatively, in New York City where patients were instructed to stay at home
until they experienced advanced symptoms, CXR was often abnormal at the time of
presentation. Equipment portability with imaging performed within an infected patient’s
isolation room is another factor that may favor CXR in selected populations, effectively
eliminating the risk of COVID-19 transmission along the transport route to a CT scanner and
within the room housing a CT scanner, particularly in environments lacking PPE. In hospitalized
patients CXR can be useful for assessing disease progression and alternative diagnoses such as
lobar pneumonia, suggestive of bacterial superinfection, pneumothorax and pleural effusion.
CT is more sensitive for early parenchymal lung disease, disease progression, and alternative
diagnoses including acute heart failure from COVID-19 myocardial injury (18) and when
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acquired with intravenous contrast material, pulmonary thromboembolism. Leveraging these
superior capabilities depends upon the availability of CT capacity, particularly considering the
potential reduction in CT scanner availability due to the additional time required to clean and
disinfect equipment following imaging of patients with suspected COVID-19. Some centers rely
on the improved depiction of COVID-19 findings with CT relative to CXR (19) and their
association with clinical worsening to determine patient disposition to home, hospital
admission, or intensive care. In recognition of variance amongst local practice patterns and
resource availability, it is important to state at the outset that the scenarios specify the use of
imaging but do not articulate the relative merit of CXR versus CT. Ultimately, the choice of
imaging modality is left to the judgement of clinical teams at the point-of-care accounting for
the differing attributes of CXR and CT, local resources, and expertise.

Overview of Clinical Scenarios
The scenarios apply only to patients presenting with features consistent with COVID-19
infection. The severity of respiratory disease and pre-test probability of COVID-19 infection are
specified for each scenario, with additional key considerations including the presence of risk
factors for disease progression, evidence of disease progression, and the presence of significant
critical resource constraints (Table 1). The scenarios distinguish mild respiratory disease from
moderate-to-severe respiratory disease based on the absence vs. presence of significant
pulmonary dysfunction or damage. Pre-test probability is defined by the background
prevalence of infection and can be estimated by observed transmission patterns: low by
sporadic transmission; moderate by clustered transmission; and high by community
transmission (20). Individual pre-test probability is further modified if there is known exposure
through contact with a confirmed case of COVID-19 (21). For health care providers, the CDC
categorizes medical-related exposures into low, medium, and high-risk groups (22). Within a
diagnostic radiology department, brief (a few minutes or less) unprotected interaction with a
patient with COVID-19 as well as prolonged close contact with a masked, infected patient by a
medical provider wearing PPE are categorized as low-risk exposures (21, 22). Risk factors for
poor outcomes in patients with COVID-19 infection are considered separately from pre-test
8

probability, with common risk factors including age > 65 years, cardiovascular disease, diabetes,
chronic respiratory disease, hypertension, and immune-compromised (23). Identifying a patient
as being at high risk for COVID-19 progression is not necessarily a feature of any single risk
factor, but is rather a clinical judgement based on the combination of underlying comorbidities
and general health status that suggests a higher level of clinical concern. Where appropriate,
management variations based upon risk factors for disease progression are called out explicitly,
as in Scenario 1. All clinical scenarios begin by characterizing COVID-19 status based upon the
availability of laboratory test results.

Scenario 1: Mild Features of COVID-19
The first scenario (Fig 1) addresses a patient presenting for evaluation at an outpatient clinic or
via telehealth with mild respiratory features consistent with COVID-19 infection, any pre-test
probability of COVID-19 infection, and no significant critical resource constraints. When COVID19 test results are unavailable, patients with moderate-to-high pre-test probability should be
initially managed as if COVID-19 testing is positive, while patients with low pre-test probability
should be initially managed as if COVID-19 testing is negative. Imaging is advised for patients
with risk factors for COVID-19 progression and either positive COVID-19 testing or moderate-tohigh pre-test probability in the absence of COVID-19 testing (Fig 1, Q1). Imaging provides a
baseline for future comparison, may establish manifestations of important comorbidities in
patients with risk factors for disease progression (Table 1), and may influence the intensity of
monitoring for clinical worsening. Imaging is not advised for patients with mild features who
are COVID-19 positive without accompanying risk factors for disease progression, or for
patients with mild features who are COVID-19 negative (Fig 1, Q2 & Q3). The panel felt that the
yield of imaging in these settings would be very low and that it was safe for most patients to
self-monitor for clinical worsening. Regardless of COVID-19 test results and risk factors, imaging
is advised for patients with mild clinical features who subsequently develop clinical worsening
(Fig 1, Q4 & Q5). In the absence of clinical worsening, management involves support and
isolation of patients with positive COVID-19 testing or patients with moderate to high pre-test
probability without COVID-19 test results available.
9

Although not specifically addressed by this scenario, in the presence of significant resources
constraints, there is no role for imaging of patients with mild features of COVID-19.

Scenario 2: Moderate to Severe Features of COVID-19
The second scenario (Fig 2) addresses a patient presenting with moderate-to-severe features
consistent with COVID-19 infection, any pre-test probability of COVID-19 infection, and no
significant critical resource constraints. Separate ratings were obtained for COVID-19 positive
patients and either COVID-19 negative patients or patients for whom COVID-19 testing is
unavailable (Fig 2, Q6 & Q7). Imaging is advised regardless of the results or availability of
COVID-19 testing given the impact of imaging in both circumstances.
For COVID-19 positive patients, imaging establishes baseline pulmonary status and identifies
underlying cardiopulmonary abnormalities that may facilitate risk stratification for clinical
worsening. In the presence of clinical worsening, imaging is again advised to assess for COVID19 progression or secondary cardiopulmonary abnormalities such as pulmonary embolism,
superimposed bacterial pneumonia, or heart failure that can potentially be secondary to
COVID-19 myocardial injury (Fig 2, Q8).
For COVID-19 negative patients or any patient for whom testing is not performed, imaging may
reveal an alternative diagnosis to explain the patient’s clinical features, which should direct
patient care as per existing clinical guidelines or standard clinical practice. If an alternative
diagnosis is not revealed or images demonstrate features of COVID-19 infection, then
subsequent clinical evaluation would depend upon the pre-test probability of COVID-19
infection and COVID-19 test availability. Falsely negative COVID-19 testing is more prevalent in
high pre-test probability circumstances and repeat COVID-19 testing is therefore advised if
available. Depending upon the imaging findings, other clinical investigations may be pursued.

10

Scenario 3: Moderate-to-Severe Features of COVID-19 in a Resource Constrained
Environment
The third scenario (Fig 3) addresses a patient presenting with moderate-to-severe features
consistent with COVID-19 infection within an environment of high community disease burden
and critical resource limitations as seen in Wuhan, China, in regions of Italy and Spain, and in
New York City. Because healthcare personnel and infrastructure may be overwhelmed by a high
influx of new patients and resources are limited to provide critical care, urgent decision-making
and triage are of primary importance. At the time of this writing, turnaround times for COVID19 test results range from 6 to over 48 hours with most sites waiting at least 12 hours for
results. This is an impractically long time period to consider triage to limited hospital beds and
ventilators. However, rapid point-of-care (PoC) COVID-19 tests are expected to be released into
clinical environments during the first week of April 2020, providing routine turnaround times of
less than an hour and potentially as little as 5 minutes (24-27). While the initial availability and
sample processing capacity of PoC COVID-19 testing is expected to be limited, this should
increase over time.
The third scenario first considers the potential availability of PoC COVID-19 testing. Imaging is
advised when PoC COVID-19 testing is available and positive (Fig 3, Q9) for the same reasons as
described for Scenario 2. Based upon imaging findings and clinical features, patients are
subsequently supported and monitored with a level of intensity consistent with clinical
features. Imaging is again indicated if patients subsequently clinically worsen (Fig 3, Q11).
Imaging is advised to support more rapid triage of patients in a resource-constrained setting
when PoC COVID-19 testing is not available or negative (Fig 3, Q10). Imaging may reveal
features of COVID-19, which within this scenario may be taken as a presumptive diagnosis of
COVID-19 for medical triage and associated decisions regarding disposition, infection control,
and clinical management. In this high pre-test probability environment, and as described for
Scenario 2, the possibility of falsely negative COVID-19 testing creates a circumstance where a
COVID-19 diagnosis may be presumed when imaging findings are strongly suggestive of COVID-
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19 despite negative COVID-19 testing. This guidance represents a variance from other published
recommendations which advise against the use of imaging for the initial diagnosis of COVID-19
(28) and was supported by direct experience amongst panelists providing care within the
conditions described for this scenario. The relationship between disease severity and triage
may need to be fluid depending upon resources and case load. When imaging reveals an
alternative diagnosis to COVID-19, management is based upon established guidelines or
standard clinical practice.

Additional Key Questions:
Daily chest radiographs are not indicated in stable intubated patients with COVID-19 (Q12)
Multiple studies have shown no difference in important outcomes (mortality, length of stay,
and ventilator days) for intensive care unit patients imaged on-demand as compared to a daily
routine protocol (29-32). Avoidance of non-value-added imaging is particularly important in the
COVID-19 patient population to minimize exposure risk of radiology technologists and to
conserve PPE.

CT scan is indicated in a patient who has functional impairment and/or hypoxemia after
recovery from COVID-19 (Q13)
With the recent emergence of SARS-CoV2 as a human pathogen, there are no long-term followup studies of survivors. Postmortem evaluation of a single patient who succumbed to severe
COVID-19 showed pathologic findings consistent with diffuse alveolar damage, similar to
findings previously described with severe acute respiratory syndrome (SARS) and Middle East
respiratory syndrome (MERS) (33). Patients with functional impairment following recovery from
COVID-19 should undergo imaging to differentiate between expected morphologic
abnormalities as sequelae of infection, mechanical ventilation, or both versus a different and
potentially treatable process.

12

COVID-19 testing is indicated in a patient who is found incidentally to have typical findings of
COVID-19 on a CT scan. (Q14)
While CT findings of COVID-19 infection are nonspecific, their presence in an asymptomatic
patient with no or mild respiratory symptoms is concerning in a setting of known community
transmission, particularly if there is no better alternative diagnosis. Asymptomatic carriers of
COVID-19 have been estimated to comprise 17.9% - 33.3% of all infected cases (34, 35).
Asymptomatic infection with suggestive CT findings in the lung has been documented in
screened cruise ship passengers (11). It is believed that the presence of undetected infected
and mildly symptomatic or asymptomatic individuals may be contributing to the rapid
geographic spread of SARS-CoV2 (9). RT-PCR testing in this scenario is important to potentially
identify an occult infection and limit further transmission both within the community and in the
environment where the patient is receiving medical care. In highly prevalent areas, an
additional uncertainty is whether CT should be used as a screening tool either as a stand-alone
or as an adjunct to RT-PCR to exclude occult infection prior to surgery or intensive
immunosuppressive therapies.
The panel’s ratings are provided in Figure 4, and a summary of all recommendations is provided
in Table 2.

Additional Resources
For purposes of image interpretation and reporting, readers are referred to a recently
published systematic review of imaging findings of COVID-19 (36) and a multi-society consensus
paper on reporting chest CT findings related to COVID-19 (37). As an aid to improving
radiologist and pulmonologist familiarity with the imaging findings of COVID-19, we provide the
following link (https://www.fleischner-covid19.org) to the Fleischner Society website where an
educational repository of proven COVID-19 cases can be found.

Conclusion
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This statement is intended to offer guidance to physicians on the use of thoracic imaging across
a breadth of healthcare environments. It represents the collective opinions and perspectives of
thoracic radiology, pulmonology, intensive care, emergency medicine, laboratory medicine, and
infection control experts practicing in 10 countries, representative of the highest burden of
COVID-19 worldwide. It also represents opinion at a moment in time within a highly-dynamic
environment where the status of regional epidemics and the availability of critical resources to
combat those epidemics vary daily. The evidence base supporting the use of imaging across the
scenarios presented is scant and the advice presented herein may undergo refinement through
rigorous scientific investigation, exposing nuances of image interpretation that may lead to
prognostic information and guide management decisions. At the time of this writing, no
therapy has been confirmed to alter the course of COVID-19, there is no known cure, and there
is no vaccine for prevention. As effective treatments are developed, thoracic imaging may find
new roles by establishing treatment response or characterizing patients as likely responders to
novel therapies.
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Table 1. Definitions and Criteria for Key Components of Common Clinical Scenarios
Definitions and criteria for key components of common clinical scenarios
Severity of respiratory disease
 Mild: No evidence of significant pulmonary dysfunction or damage (e.g., absence of
hypoxemia, no or mild dyspnea)
 Moderate-to-severe: Evidence of significant pulmonary dysfunction or damage (e.g.,
hypoxemia, moderate-to-severe dyspnea)
Pre-test probability
 Based upon background prevalence of disease as estimated by observed transmission
patterns. May be further modified by individual’s exposure risk. Sub-categorized as:
o Low: Sporadic transmission
o Medium: Clustered transmission
o High: Community transmission
Risk factors for disease progression
 Present: Clinical judgement regarding combination of age > 65 years and presence of
comorbidities (e.g., cardiovascular disease, diabetes, chronic respiratory disease,
hypertension, immune-compromised)
 Absent: Defined by the absence of risk factors for disease progression
Disease progression
 Progression of mild disease to moderate-to-severe disease as defined above.
 Progression of moderate-to-severe disease with worsening objective measures of
hypoxemia.
Resource constraints
 Limited access to personnel, personal protective equipment, COVID-19 testing ability
(including swabs, reagent, or personnel), hospital beds, and/or ventilators with the
need to rapidly triage patients.
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Table 2. Summary of Recommendations for Imaging
Summary of Recommendations for Imaging
Main Recommendations
 Imaging is not routinely indicated as a screening test for COVID-19 in asymptomatic
individuals
 Imaging is not indicated for patients with mild features of COVID-19 unless they are at
risk for disease progression (Scenario 1)
 Imaging is indicated for patients with moderate to severe features of COVID-19
regardless of COVID-19 test results (Scenarios 2 and 3)
 Imaging is indicated for patients with COVID-19 and evidence of worsening
respiratory status (Scenarios 1, 2, and 3)
 In a resource constrained environment where access to CT is limited, CXR may be
preferred for patients with COVID-19 unless features of respiratory worsening
warrant the use of CT (Scenarios 2 and 3)
Additional Recommendations
 Daily chest radiographs are NOT indicated in stable intubated patients with COVID-19
 CT is indicated in patients with functional impairment and/or hypoxemia after
recovery from COVID-19
 COVID-19 testing is indicated in patients incidentally found to have findings suggestive
of COVID-19 on a CT scan
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Figure 1: The first of three clinical scenarios presented to the panel with final
recommendations. Mild features refer to absence of significant pulmonary dysfunction or
damage. Pre-test probability is based upon background prevalence of disease and may be
further modified by individual’s exposure risk. The absence of resource constraints corresponds
to sufficient availability of personnel, personal protective equipment, COVID-19 testing,
hospital beds, and/or ventilators with the need to rapidly triage patients. Numbers in blue
circles indicate key questions referenced in the text and presented in Figure 4. Contextual detail
and considerations for imaging with CXR (chest radiography) versus CT (computed tomography)
are presented in the text. (Pos=positive, Neg=negative, Mod=moderate). [Although not covered
by this scenario and not shown in the figure, in the presence of significant resources
constraints, there is no role for imaging of patients with mild features of COVID-19.]
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Figure 2: The second of three clinical scenarios presented to the panel with final
recommendations. Moderate-to-severe features refer to evidence of significant pulmonary
dysfunction or damage. Pre-test probability is based upon background prevalence of disease
and may be further modified by individual’s exposure risk. The absence of resource constraints
corresponds to sufficient availability of personnel, personal protective equipment, COVID-19
testing, hospital beds, and/or ventilators with the need to rapidly triage patients. Numbers in
blue circles indicate key questions referenced in the text and presented in Figure 4. Contextual
detail and considerations for imaging with CXR (chest radiography) versus CT (computed
tomography) are presented in the text. (Pos=positive, Neg=negative, Alt Dx=alternate
diagnosis).
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Figure 3: The third of three clinical scenarios presented to the panel with final
recommendations. Moderate-to-severe features refer to evidence of significant pulmonary
dysfunction or damage. High pre-test probability is based upon high background prevalence of
disease associated with community transmission. Rapid COVID-19 test is a point-of-care test
with a less than one-hour turnaround time. Numbers in blue circles indicate key questions
referenced in the text and presented in Figure 4. Contextual detail and considerations for
imaging with CXR (chest radiography) versus CT (computed tomography) are presented in the
text. (Pos=positive, Neg=negative, Alt Dx=alternate diagnosis).
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Figure 4: Panel members (total n=27) developed 14 key questions (numerals in left column
correspond to question numbers in text and Figures 1-3) that were used to support creation of
common scenarios and recommendations related to the use of chest imaging in patients with
features of COVID-19. The proportion of panel member votes for each question is presented on
a 5-point scale, as well as a summary column that shows the total percentage who voted for or
against imaging for each key question, excluding those members who were neutral or who
abstained (1 panel member abstained for questions 1 and 2).
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